Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance

Substance Abuse Treatment, Prevention, and Policy

Reinhart Jarisch³  Bernhard Spitzer²  Augustin Pollesböck²  Dagmara Loader³  Christina Fellinger³  Carola Kager³  Ute Maurer¹ 

[1] Department: Health, Biomedical Science, University of Applied Sciences Wiener Neustadt, Johannes Gutenberg-Strasse 3, 2700 Wiener Neustadt, Austria;Landesklinikum Mauer, Withdrawal Centre, Hausmeninger Straße 221, 3362 Mauer/Amstetten, Austria;Floridsdorfer Allergy Centre (FAZ), Franz Jonasplatz 8, 1210 Vienna, Austria

关键词: Opioid;    Histamine;    Anaphylaxis;    Drug Addiction;   

Others  :  833345
DOI  :  10.1186/1747-597X-9-12

 received in 2013-10-25, accepted in 2014-02-21,  发布年份 2014

【 摘 要 】

Background

Across Europe, illicit drug-related mortality has not declined despite ever increasing prevention measures. The cause of these deaths has traditionally been associated with overdose. Previous findings have revealed the appearance of non-lethal opioid concentrations, leading us to investigate a further cause of death. The symptoms of heroin intoxication with asphyxia and/or cardiovascular involvement resemble anaphylaxis, and therefore it has been speculated that such deaths might be caused by an allergic reaction. The study´s aims were to investigate levels of allergic mediators in long-term injecting drug users (IDU) compared to healthy controls and to determine if oral opioid substitution therapy (OST) resulted in similar allergic symptoms to those reported by IDU after intravenous (IV) heroin use.

Methods

We quantified the concentrations of histamine, diamine oxidase (DAO), tryptase and lipoprotein-associated phospholipase A₂ (LpPLA₂) at baseline and 1 h after administration of Substitol®retard (482 ± 220 mg) in 56 patients at a withdrawal centre (Austria) and compared them with healthy controls (n = 103). Questionnaires and face-to-face interviews were used to assess allergic symptoms and side effects in IDU. Descriptive statistical analyses of quantitative data were performed by using SPSS.

Results

Baseline histamine, tryptase and LpPLA₂ were significantly elevated in IDU compared to the healthy control group, while DAO decreased. Blood levels showed no significant change after oral substitution uptake. Self-reported allergic symptoms and side effects after IV heroin use were reported in 55 cases (98.2%), minimal symptoms were documented after OST (12.5%, 7/56).

Conclusions

This study revealed that baseline histamine concentrations were elevated in chronic IDU, although only relatively small changes in tryptase plasma levels occurred. After IV heroin application the reported allergic symptoms were mostly mild and did not lead to clinically relevant side effects. The substitution substance was clearly better tolerated than IV administered heroin. Elevated levels of allergic mediators such as histamine in IDUs may place them at greater risk of severe or fatal anaphylaxis when exposed to heroin; however, this requires further investigation.

【 授权许可】

   
2014 Maurer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Risser D, Honigschnabl S, Stichenwirth M, Pfudl S, Sebald D, Kaff A, Bauer G: Mortality of opiate users in Vienna, Austria. Drug Alcohol Depend 2001, 64(3):251-256.
• [2]Risser D, Schneider B: Drug-related deaths between 1985 and 1992 examined at the Institute of Forensic Medicine in Vienna, Austria. Addiction 1994, 89(7):851-857.
• [3]Darke S, Zador D: Fatal heroin 'overdose': a review. Addiction 1996, 91(12):1765-1772.
• [4]Staub C, Jeanmonod R, Fryc O: Morphine in postmortem blood: its importance for the diagnosis of deaths associated with opiate addiction. Int J Legal Med 1990, 104(1):39-42.
• [5]Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M: Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013, 91(2):102-123.
• [6]Polettini A, Poloni V, Groppi A, Stramesi C, Vignali C, Politi L, Montagna M: The role of cocaine in heroin-related deaths. Hypothesis on the interaction between heroin and cocaine. Forensic Sci Int 2005, 153(1):23-28.
• [7]Simons FE: 9. Anaphylaxis. J Allergy Clin Immunol 2008, 121(2 Supp):S402-S407. quiz S420
• [8]Simons FE: Anaphylaxis. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S161-S181.
• [9]Simons FE: World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings. Ann Allergy Asthma Immunol 2010, 104(5):405-412.
• [10]Ben-Shoshan M, Clarke AE: Anaphylaxis: past, present and future. Allergy 2011, 66(1):1-14.
• [11]Pumphrey R: Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004, 4(4):285-290.
• [12]Tsai MG, S. G : Mast cells: effector cells of anaphylaxis. In Anaphylaxis and Hypersensitivity Reactions. Edited by Castells MC. New York: Humana Press; 2011:47-68.
• [13]Lee JK, Vadas P: Anaphylaxis: mechanisms and management. Clin Exp Allergy 2011, 41(7):923-938.
• [14]Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG: Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol 2009, 124(4):786-792. e784
• [15]Stone KD, Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S73-S80.
• [16]Schwartz LB: Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004, 257:65-74. discussion 74-69, 98-100, 276-185
• [17]Simons FE, Sampson HA: Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol 2008, 122(6):1166-1168.
• [18]Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117(2):391-397.
• [19]Sanz ML, Gamboa PM, Garcia-Figueroa BE, Ferrer M: In vitro Diagnosis of Anaphylaxis. In Anaphylaxis Chemical Immunology and Allergy, Volume 95. Edited by Ring J. Basel: Kager; 2010:125-140.
• [20]Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D: Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989, 83(5):1551-1555.
• [21]Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006, 26(3):451-463.
• [22]Baldo BA, Pham NH: Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care 2012, 40(2):216-235.
• [23]Veien M, Szlam F, Holden JT, Yamaguchi K, Denson DD, Levy JH: Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000, 92(4):1074-1081.
• [24]Stellato C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G: Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology 1992, 77(5):932-940.
• [25]Organization WH: ICD-10, the ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization; 1993.
• [26]Union E: EU Drugs Strategy (2013-2020). 2012.
• [27]Dale HH, Laidlaw PP: The physiological action of beta-iminazolylethylamine. J Physiol 1910, 41(5):318-344.
• [28]Parsons ME, Ganellin CR: Histamine and its receptors. Br J Pharmacol 2006, 147(Suppl 1):S127-S135.
• [29]Di Bello MG, Masini E, Ioannides C, Ndisang JF, Raspanti S, Bani Sacchi T, Mannaioni PF: Histamine release from rat mast cells induced by the metabolic activation of drugs of abuse into free radicals. Inflamm Res 1998, 47(3):122-130.
• [30]Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA: Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985, 62(2):124-129.
• [31]Immunotech BCC: RIA Histamine, Immunradiometrischer Assay für die quantitative in vitro Bestimmung von Histamin in biologischen Proben. Immunotech SAS; 1-18.
• [32]Jarisch R: Histamin-Intoleranz, Histamin und Seekrankheit. Stuttgart: Thieme Verlag; 2013.
• [33]Luk GD, Bayless TM, Baylin SB: Diamine oxidase (histaminase): a circulating marker for rat intestinal mucosal maturation and integrity. J Clin Invest 1980, 66(1):66-70.
• [34]Raithel M, Ulrich P, Hochberger J, Hahn EG: Measurement of gut diamine oxidase activity. Diamine oxidase as a new biologic marker of colorectal proliferation? Ann N Y Acad Sci 1998, 859:262-266.
• [35]Mayer DE, Krauskopf A, Hemmer W, Moritz K, Jarisch R, Reiter C: Usefulness of post mortem determination of serum tryptase, histamine and diamine oxidase in the diagnosis of fatal anaphylaxis. Forensic Sci Int 2011, 212(1–3):96-101.
• [36]Diaminoxidase (DAO), Radioextraktionsassay (REA) zur quantitativen Bestimmung der DAO-Aktivität Serum und Plasma [http://www.sciotec.at/en/products/diagnostics/ webcite]
• [37]Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987, 316(26):1622-1626.
• [38]Payne V, Kam PC: Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004, 59(7):695-703.
• [39]Test Principle ImmunoCAP Tryptase [http://www.phadia.com/da/Products/Allergy-testing-products/ImmunoCAP-Assays/ImmunoCAP-Tryptase/ webcite]
• [40]Dada N, Kim NW, Wolfert RL: Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2002, 2(1):17-22.
• [41]Carlquist JF, Muhlestein JB, Anderson JL: Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007, 7(5):511-517.
• [42]Zalewski A, Nelson JJ, Hegg L, Macphee C: Lp-PLA2: a new kid on the block. Clin Chem 2006, 52(9):1645-1650.
• [43]The PLAC Test ELISA Kit [http://www.plactest.com/international/package-insert-plac-test-elisa-kit webcite]
• [44]Hirshman CA, Downes H, Butler S: Relevance of plasma histamine levels to hypotension. Anesthesiology 1982, 57(5):424-426.
• [45]Fahmy NR, Sunder N, Soter NA: Role of histamine in the hemodynamic and plasma catecholamine responses to morphine. Clin Pharmacol Ther 1983, 33(5):615-620.
• [46]Barke KE, Hough LB: Opiates, mast cells and histamine release. Life Sci 1993, 53(18):1391-1399.
• [47]Marone G, Stellato C, Mastronardi P, Mazzarella B: Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Annales francaises d'anesthesie et de reanimation 1993, 12(2):116-125.
• [48]Levy JH, Brister NW, Shearin A, Ziegler J, Hug CC Jr, Adelson DM, Walker BF: Wheal and flare responses to opioids in humans. Anesthesiology 1989, 70(5):756-760.
• [49]Leysen J, De Witte L, Sabato V, Faber M, Hagendorens M, Bridts C, De Clerck L, Ebo D: IgE-mediated allergy to pholcodine and cross-reactivity to neuromuscular blocking agents: Lessons from flow cytometry. Cytometry B Clin Cytom 2013, 84(2):65-70.
• [50]Edston E, van Hage-Hamsten M: beta-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci Int 1998, 93(2-3):135-142.
• [51]Edston E, van Hage-Hamsten M: Anaphylactoid shock–a common cause of death in heroin addicts? Allergy 1997, 52(9):950-954.
• [52]Rook EJ, Hillebrand MJ, Rosing H, van Ree JM, Beijnen JH: The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 824(1–2):213-221.
• [53]Karasuyama H, Mukai K, Tsujimura Y, Obata K: Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol 2009, 9(1):9-13.
• [54]Mukai K, Obata K, Tsujimura Y, Karasuyama H: [The roles for basophils in allergy]. Nihon Rinsho 2009, 67(11):2095-2099.
• [55]Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, Maerz W, Brenner H, Koenig W: Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005, 182(1):181-188.
• [56]Haemmig RB, Tschacher W: Effects of high-dose heroin versus morphine in intravenous drug users: a randomised double-blind crossover study. J Psychoactive Drugs 2001, 33(2):105-110.
• [57]Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB: Morphine-induced venodilation in humans. Clin Pharmacol Ther 1996, 60(5):554-560.
• [58]Schug SA, Zech D, Grond S: Adverse effects of systemic opioid analgesics. Drug Saf 1992, 7(3):200-213.
• [59]Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378(9791):571-583.
• [60]Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P: Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993, 22(2):315-320.